Feel the Pain

With the conference winding down, you can clearly feel the change in emotion throughout the halls, lobby and conference rooms of the St. Frances. What was once a vibrant and high energy crowd is now a dwindling group of tired and emotionally drained individuals. To navigate through the H&Q conference successfully, one needs stamina, good shoes and a strong posture. Call it coincidence, but the majority of companies I met with on Thursday were in the CNS field. My conclusion: The majority of

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
With the conference winding down, you can clearly feel the change in emotion throughout the halls, lobby and conference rooms of the St. Frances. What was once a vibrant and high energy crowd is now a dwindling group of tired and emotionally drained individuals. To navigate through the H&Q conference successfully, one needs stamina, good shoes and a strong posture. Call it coincidence, but the majority of companies I met with on Thursday were in the CNS field. My conclusion: The majority of this year?s deal flow will come out of the CNS sector. The compounds companies want to see the most? in the words of Clubber Lang in Rocky III: ?I predict pain.? Although many companies want to acquire pain compounds, there are very few products readily available. This leads me to believe that companies looking to acquire pain products will likely search for early clinical stage or even preclinical products. The other theme I found interesting was that many biotech executives have expressed interest in acquiring reformulated compounds. The companies expressing interest have ranged from investors looking to start new companies to well established companies looking to diversify their pipelines. This probably isn?t a bad strategy considering there is less inherent clinical risk involved in developing reformulated drugs. Anonymous quote of the day: ?I love biotechnology because there is no other job in the world where I can invest my time building companies that will make my children live healthier and longer lives.?
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Justin Silver

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours